Denis Duboc

List of Publications by Citations

48 papers	6,301 citations	26 h-index	52 g-index
52 ext. papers	7,227 ext. citations	9.5 avg, IF	4.64 L-index

#	Paper	IF	Citations
48	Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. *Nature Genetics*, **1999**, 21, 285-8	36.3	1076
47	Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. *Journal of the American College of Cardiology*, **2003**, 41, 1078-83	15.1	933
46	Myoblast transplantation for heart failure. *Lancet, The*, **2001**, 357, 279-80	40	886
45	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. *European Heart Journal*, **2016**, 37, 1850-8	9.5	473
44	Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death?. *Journal of Molecular Medicine*, **2005**, 83, 79-83	5.5	326
43	Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. *Journal of the American College of Cardiology*, **2005**, 45, 855-7	15.1	305
42	Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy. *Lancet, The*, **2003**, 361, 491-2	40	233
41	Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. *American Heart Journal*, **2007**, 154, 596-602	4.9	232
40	Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. *Nature Structural and Molecular Biology*, **2011**, 18, 840-5	17.6	212
39	Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients. *Circulation*, **2006**, 114, I108-13	16.7	199
38	High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. *PACE - Pacing and Clinical Electrophysiology*, **2000**, 23, 1661-6	1.6	198
37	Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. *Chest*, **2002**, 122, 1895-901	5.3	190
36	Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter diagnostic pacemaker study. *Journal of the American College of Cardiology*, **2002**, 40, 1645-52	15.1	147
35	Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. *JAMA - Journal of the American Medical Association*, **2012**, 307, 1292-301	27.4	118
34	Splicing misregulation of SCN5A contributes to cardiac-conduction delay and heart arrhythmia in myotonic dystrophy. *Nature Communications*, **2016**, 7, 11067	17.4	101
33	Does the functional efficacy of skeletal myoblast transplantation extend to nonischemic cardiomyopathy?. *Circulation*, **2004**, 110, 1626-31	16.7	67
32	Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. *Circulation*, **2019**, 140, 293-302	16.7	63

31	Cardiac assessment of limb-girdle muscular dystrophy 2I patients: an echography, Holter ECG and magnetic resonance imaging study. *Neuromuscular Disorders*, **2008**, 18, 650-5	2.9	48
30	Long-term cardiac prognosis and risk stratification in 260 adults presenting with mitochondrial diseases. *European Heart Journal*, **2015**, 36, 2886-93	9.5	46
29	Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. *European Heart Journal*, **2017**, 38, 751-758	9.5	44
28	Brugada syndrome and abnormal splicing of SCN5A in myotonic dystrophy type 1. *Archives of Cardiovascular Diseases*, **2013**, 106, 635-43	2.7	43
27	Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients. *Rheumatology*, **2013**, 52, 642-50	3.9	40
26	Is skeletal myoblast transplantation clinically relevant in the era of angiotensin-converting enzyme inhibitors?. *Circulation*, **2001**, 104, I223-8	16.7	40
25	Giant coronary aneurysms, from diagnosis to treatment: A literature review. *Archives of Cardiovascular Diseases*, **2020**, 113, 59-69	2.7	31
24	Comparison of single-shot fast spin-echo and conventional spin-echo sequences for MR imaging of the heart: initial experience. *Radiology*, **2001**, 219, 545-50	20.5	30
23	Association Between Mutation Size and Cardiac Involvement in Myotonic Dystrophy Type 1: An Analysis of the DM1-Heart Registry. *Circulation: Cardiovascular Genetics*, **2017**, 10,		27
22	Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: A long-term retrospective study on 42 patients. *Autoimmunity Reviews*, **2015**, 14, 774-80	13.6	26
21	Abnormal sodium current properties contribute to cardiac electrical and contractile dysfunction in a mouse model of myotonic dystrophy type 1. *Neuromuscular Disorders*, **2015**, 25, 308-20	2.9	20
20	Relationship between cardiac arrhythmias and sleep apnoea in permanently paced patients with type I myotonic dystrophy. *Neuromuscular Disorders*, **2007**, 17, 392-9	2.9	16
19	Development and Validation of a New Scoring System to Predict Survival in Patients With Myotonic Dystrophy Type 1. *JAMA Neurology*, **2018**, 75, 573-581	17.2	15
18	Clinical Care Recommendations for Cardiologists Treating Adults With Myotonic Dystrophy. *Journal of the American Heart Association*, **2020**, 9, e014006	6	13
17	Atrial flutter in myotonic dystrophy type 1: Patient characteristics and clinical outcome. *Neuromuscular Disorders*, **2016**, 26, 227-33	2.9	12
16	Atrio-ventricular block requiring pacemaker in patients with late onset Pompe disease. *Neuromuscular Disorders*, **2014**, 24, 648-50	2.9	12
15	Patient journey in decompensated heart failure: An analysis in departments of cardiology and geriatrics in the Greater Paris University Hospitals. *Archives of Cardiovascular Diseases*, **2017**, 110, 42-50	2.7	10
14	Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data. *European Heart Journal*, **2021**, 42, 1976-1984	9.5	8

13	Left bundle branch block in Duchenne muscular dystrophy: Prevalence, genetic relationship and prognosis. *PLoS ONE*, **2018**, 13, e0190518	3.7	5
12	Risk for Complications after Pacemaker or Cardioverter Defibrillator Implantations in Patients with Myotonic Dystrophy Type 1. *Journal of Neuromuscular Diseases*, **2017**, 4, 175-181	5	5
11	Incidence and predictors of total mortality in 267 adults presenting with mitochondrial diseases. *Journal of Inherited Metabolic Disease*, **2020**, 43, 459-466	5.4	5
10	N-terminal Pro brain natriuretic peptide is a reliable biomarker of reduced myocardial contractility in patients with lamin A/C gene mutations. *International Journal of Cardiology*, **2011**, 151, 160-3	3.2	4
9	238th ENMC International Workshop: Updating management recommendations of cardiac dystrophinopathyHoofddorp, The Netherlands, 30 November - 2 December 2018. *Neuromuscular Disorders*, **2019**, 29, 634-643	2.9	3
8	Reduced inotropic reserve is predictive of further degradation in left ventricular ejection fraction in patients with Duchenne muscular dystrophy. *European Journal of Heart Failure*, **2015**, 17, 177-81	12.3	2
7	Circulating bile acids concentration is predictive of coronary artery disease in human. *Scientific Reports*, **2021**, 11, 22661	4.9	2
6	A high prevalence of arterial hypertension in patients with mitochondrial diseases. *Journal of Inherited Metabolic Disease*, **2020**, 43, 478-485	5.4	2
5	High Risk of Fatal and Nonfatal Venous Thromboembolism in Myotonic Dystrophy. *Circulation*, **2018** , 138, 1169-1171	16.7	2
4	Cardiac involvement in laminopathies. *Orphanet Journal of Rare Diseases*, **2015**, 10, O25	4.2	1
3	Perindopril preserves left ventricular function in X-linked Duchenne muscular dystrophy. *Country Review Ukraine*, **2007**, 9, E20-E24		1
2	How should physicians manage patients with Duchenne muscular dystrophy when experts recommendations are not unanimous?. *Developmental Medicine and Child Neurology*, **2007**, 48, 863-864	3.3	
1	Improved Cardiac Outcomes by Early Treatment with Angiotensin-Converting Enzyme Inhibitors in Becker Muscular Dystrophy. *Journal of Neuromuscular Diseases*, **2021**, 8, 495-502	5	